Trial Profile
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary) ; Adalimumab; Ciclosporin; Leflunomide; Methotrexate; Sulfasalazine
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms SPIRIT-H2H
- Sponsors Eli Lilly and Company
- 15 Nov 2023 Results (n=354) of a post-hoc analysis assessing treatment effects of IXE and ADA at individual digit level among patients with PsA, nail PsO, and adjacent joint disease presented at the ACR Convergence 2023
- 03 Jun 2023 Results of post hoc analysis comparatively assessing the effect of ixekizumab and adalimumab at the individual digit level in improving nail and joint disease, in patients with PsA and concomitant nail involvement, presented at the 24th Annual Congress of the European League Against Rheumatism
- 21 Mar 2023 Results of post-hoc pooled analysis assessing patient-reported fatigue, using the SF-36 vitality domain, in patients who received ixekizumab 80 mg Q2W for 12 weeks for moderate-to-severe psoriasis across UNCOVER-1 (N=433), UNCOVER-2 (N=351), UNCOVER-3 (N=385), and IXORA-S (N=136) SPIRIT-H2H presented at the American Academy of Dermatology annual Meeting 2023